StockNews.com Begins Coverage on Evogene (NASDAQ:EVGN)

StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a research report sent to investors on Thursday morning. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Lake Street Capital lowered their price target on Evogene from $30.00 to $12.00 and set a “buy” rating for the company in a report on Friday, August 23rd.

Evogene Price Performance

Shares of NASDAQ:EVGN opened at $1.33 on Thursday. Evogene has a 1 year low of $1.26 and a 1 year high of $10.40. The company’s 50 day simple moving average is $2.02 and its 200 day simple moving average is $3.90.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC bought a new stake in Evogene Ltd. (NASDAQ:EVGN) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is owned by institutional investors and hedge funds.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.